Recent Advances in the Applications of Small Molecules in the Treatment of Multiple Myeloma

Cancer statistics, 2022

(2022) Rebecca L. Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

NCCN Guidelines® Insights: Multiple Myeloma, Version 3.2022

(2022) Natalie S. Callander et al.   Journal of the National Comprehensive Cancer Network

PROTAC targeted protein degraders: the past is prologue

(2022) Miklós Békés et al.   NATURE REVIEWS DRUG DISCOVERY

Modulation of cellular processes by histone and non-histone protein acetylation

(2022) Maria Shvedunova et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY

Melflufen or pomalidomide plus dexamethasone for patients with multiple myeloma refractory to lenalidomide (OCEAN): a randomised, head-to-head, open-label, phase 3 study

(2022) Fredrik H Schjesvold et al.   Lancet Haematology

Where We Stand With Precision Therapeutics in Myeloma: Prosperity, Promises, and Pipedreams

(2022) Darren Pan et al.   Frontiers in Oncology

Targeting Histone Deacetylases: Opportunities for Cancer Treatment and Chemoprevention

(2022) Dusan Ruzic et al.   Pharmaceutics

Kinesin spindle protein inhibitors in cancer: from high throughput screening to novel therapeutic strategies

(2022) Rand Shahin et al.   Future Science OA

Daratumumab in first-line is cost-effective in transplant-eligible newly diagnosed myeloma patients.

(2022) Chihiro Yamamoto et al.   BLOOD

Selinexor plus low-dose dexamethasone in Chinese patients with relapsed/refractory multiple myeloma previously treated with an immunomodulatory agent and a proteasome inhibitor (MARCH): a phase II, single-arm study

(2022) Lugui Qiu et al.   BMC Medicine

Ibrutinib, lenalidomide and dexamethasone in patients with relapsed and/or refractory multiple myeloma: Phase I trial results

(2022) Sikander Ailawadhi et al.   HEMATOLOGICAL ONCOLOGY

The approval and withdrawal of melphalan flufenamide (melflufen): Implications for the state of the FDA.

(2022) Timothée Olivier et al.   Translational Oncology

Cost-effectiveness: maximizing impact by meticulous data

(2022) Hedwig M. Blommestein et al.   BLOOD

Solving the nuclear pore puzzle

(2022) Thomas U. Schwartz   SCIENCE

Updates in the Use of BCL-2-Family Small Molecule Inhibitors for the Treatment of Relapsed/Refractory Multiple Myeloma

(2022) Ricardo D. Parrondo et al.   Cancers

Authors’ reply: Perspective: The approval and withdrawal of melphalan flufenamide (melflufen): Implications for the state of the FDA

(2022) Fredrik H Schjesvold et al.   Translational Oncology

Iberdomide plus dexamethasone in heavily pretreated late-line relapsed or refractory multiple myeloma (CC-220-MM-001): a multicentre, multicohort, open-label, phase 1/2 trial

(2022) Sagar Lonial et al.   Lancet Haematology

CRL4CRBN E3 Ligase Complex as a Therapeutic Target in Multiple Myeloma

(2022) Joanna Barankiewicz et al.   Cancers

Preliminary Results from the Launch Study-a Multicenter, Open-Label Study of Selinexor, Dexamethasone and Chemotherapy Drugs in Relapsed/ Refractory Multiple Myeloma

(2022) Chunyan Sun et al.   BLOOD

Preliminary Safety of a Bcl-2 Inhibitor, Bgb-11417, in Patients with Relapsed/Refractory Multiple Myeloma Harboring t(11,14): A Non-Randomized, Open-Label, Phase 1b/2 Study

(2022) Hang Quach et al.   BLOOD

Phase I Study of a Novel Oral Proteasome Inhibitor TQB3602 in Relapsed/Refractory Multiple Myeloma

(2022) Wenjiao Tang et al.   BLOOD

Melflufen: A Next-Generation Nitrogen Mustard

(2021) Sarah A. Holstein et al.   JOURNAL OF CLINICAL ONCOLOGY

Gain/Amplification of Chromosome Arm 1q21 in Multiple Myeloma

(2021) Ichiro Hanamura   Cancers

Combinations of histone post-translational modifications

(2021) Bethany C. Taylor et al.   BIOCHEMICAL JOURNAL

Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

(2021) Hyuna Sung et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Cancer therapies based on targeted protein degradation — lessons learned with lenalidomide

(2021) Max Jan et al.   Nature Reviews Clinical Oncology

Effect of age and frailty on the efficacy and tolerability of once‐weekly selinexor, bortezomib, and dexamethasone in previously treated multiple myeloma

(2021) Holger W. Auner et al.   AMERICAN JOURNAL OF HEMATOLOGY

Bruton’s tyrosine kinase: an emerging targeted therapy in myeloid cells within the tumor microenvironment

(2021) Logan Good et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Effect of prior treatments on selinexor, bortezomib, and dexamethasone in previously treated multiple myeloma

(2021) Maria V. Mateos et al.   Journal of Hematology & Oncology

Pharmacodynamic, pharmacokinetic, and phase 1a study of bisthianostat, a novel histone deacetylase inhibitor, for the treatment of relapsed or refractory multiple myeloma

(2021) Yu-bo Zhou et al.   ACTA PHARMACOLOGICA SINICA

Quality of life analyses in patients with multiple myeloma: results from the Selinexor (KPT-330) Treatment of Refractory Myeloma (STORM) phase 2b study

(2021) Gabriel Tremblay et al.   BMC CANCER

Optimal Supportive Care With Selinexor Improves Outcomes in Patients With Relapsed/Refractory Multiple Myeloma

(2021) Ajai Chari et al.   Clinical Lymphoma Myeloma & Leukemia

Structure-based design approach of potential BCL-2 inhibitors for cancer chemotherapy

(2021) Swati Krishna et al.   COMPUTERS IN BIOLOGY AND MEDICINE

Bromodomains: A novel target for the anticancer therapy

(2021) Shivani Gokani et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

BH3 Mimetics in Hematologic Malignancies

(2021) Pavel Klener et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Phase I Study of Venetoclax Plus Daratumumab and Dexamethasone, With or Without Bortezomib, in Patients With Relapsed or Refractory Multiple Myeloma With and Without t(11;14)

(2021) Nizar J. Bahlis et al.   JOURNAL OF CLINICAL ONCOLOGY

Once weekly selinexor, carfilzomib, and dexamethasone (XKd) in carfilzomib nonrefractory multiple myeloma (MM) patients.

(2021) Cristina Gasparetto et al.   JOURNAL OF CLINICAL ONCOLOGY

Oral selinexor, pomalidomide, and dexamethasone (XPd) at recommended phase 2 dose in relapsed refractory multiple myeloma (MM).

(2021) Darrell White et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase Ib trial of vactosertib in combination with pomalidomide in relapsed multiple myeloma: A corticosteroid-free approach by targeting TGF-β signaling pathway.

(2021) Ehsan Malek et al.   JOURNAL OF CLINICAL ONCOLOGY

Structure, Maintenance, and Regulation of Nuclear Pore Complexes: The Gatekeepers of the Eukaryotic Genome

(2021) Marcela Raices et al.   Cold Spring Harbor Perspectives in Biology

Deubiquitinases in hematological malignancies

(2021) Hu Lei et al.   Biomarker Research

Phase 2 study of venetoclax plus carfilzomib and dexamethasone in patients with relapsed/refractory multiple myeloma

(2021) Luciano J Costa et al.   Blood Advances

Incidence and Management of Carfilzomib-induced Cardiovascular Toxicity; A Systematic Review and Meta-analysis

(2021) Azka Latif et al.   Cardiovascular and Hematological Disorders - Drug Targets

A phase 1 clinical trial of oral eltanexor in patients with relapsed or refractory multiple myeloma

(2021) Robert Frank Cornell et al.   AMERICAN JOURNAL OF HEMATOLOGY

Phase 2 Suzhou MM02 Study: Chidamide with VRD Versus VRD in Newly Diagnosed High Risk Transplant Eligible Multiple Myeloma Patients

(2021) Weiqin Yao et al.   BLOOD

Trial in Progress: Phase 1b/2 Open-Label Study of Lisaftoclax (APG-2575) Monotherapy or in Combination with Lenalidomide/Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma (R/R MM)

(2021) Chengcheng Fu et al.   BLOOD

Safety and Preliminary Efficacy from the Expansion Cohort of a Phase 1/2 Study of Venetoclax Plus Daratumumab and Dexamethasone Vs Daratumumab Plus Bortezomib and Dexamethasone in Patients with t(11;14) Relapsed/Refractory Multiple Myeloma

(2021) Jonathan L. Kaufman et al.   BLOOD

Selinexor in Combination with Daratumumab-Bortezomib and Dexamethasone for the Treatment of Relapse or Refractory Multiple Myeloma: Initial Results of the Phase 2, Open-Label, Multicenter GEM-Selibordara Study

(2021) Paula Rodríguez-Otero et al.   BLOOD

Final Overall Survival Results from BELLINI, a Phase 3 Study of Venetoclax or Placebo in Combination with Bortezomib and Dexamethasone in Relapsed/Refractory Multiple Myeloma

(2021) Shaji Kumar et al.   BLOOD

P-203: EXCALIBER: a phase 3 study comparing iberdomide, daratumumab, and dexamethasone (IberDd) with daratumumab, bortezomib, and dexamethasone (DVd) in patients with relapsed or refractory multiple myeloma

(2021) Sagar Lonial et al.   Clinical Lymphoma Myeloma & Leukemia

Cardiotoxicity as an adverse effect of immunomodulatory drugs and proteasome inhibitors in multiple myeloma: A network meta‐analysis of randomized clinical trials

(2021) Avash Das et al.   HEMATOLOGICAL ONCOLOGY

Efficacy and Toxicity Profile of Carfilzomib-Based Regimens for Treatment of Newly Diagnosed Multiple Myeloma: A Systematic Review

(2021) Hassaan Imtiaz et al.   OncoTargets and Therapy

Filanesib plus bortezomib and dexamethasone in relapsed/refractory t(11;14) and 1q21 gain multiple myeloma

(2021) Darren Pan et al.   Cancer Medicine

Therapeutic targeting of “undruggable” MYC

(2021) Victor Llombart et al.   EBioMedicine

Final analysis of a phase 1/2b study of ibrutinib combined with carfilzomib/dexamethasone in patients with relapsed/refractory multiple myeloma

(2020) Ajai Chari et al.   HEMATOLOGICAL ONCOLOGY

Phase 1 study of the protein deubiquitinase inhibitor VLX1570 in patients with relapsed and/or refractory multiple myeloma

(2020) Eric K. Rowinsky et al.   INVESTIGATIONAL NEW DRUGS

Discovery of CRBN E3 Ligase Modulator CC-92480 for the Treatment of Relapsed and Refractory Multiple Myeloma

(2020) Joshua D. Hansen et al.   JOURNAL OF MEDICINAL CHEMISTRY

The Frequency of Ras Mutations in Cancer

(2020) Ian A. Prior et al.   CANCER RESEARCH

Selinexor, daratumumab, and dexamethasone in patients with relapsed/refractory multiple myeloma (MM).

(2020) Cristina Gasparetto et al.   JOURNAL OF CLINICAL ONCOLOGY

First-in-human phase I study of the novel CELMoD agent CC-92480 combined with dexamethasone (DEX) in patients (pts) with relapsed/refractory multiple myeloma (RRMM).

(2020) Paul G. Richardson et al.   JOURNAL OF CLINICAL ONCOLOGY

Once weekly selinexor, carfilzomib, and dexamethasone (SKd) in patients with relapsed/refractory multiple myeloma (MM).

(2020) Cristina Gasparetto et al.   JOURNAL OF CLINICAL ONCOLOGY

Updated results from BELLINI, a phase III study of venetoclax or placebo in combination with bortezomib and dexamethasone in relapsed/refractory multiple myeloma.

(2020) Shaji Kumar et al.   JOURNAL OF CLINICAL ONCOLOGY

A phase III, randomized, multicenter, open-label study of venetoclax or pomalidomide in combination with dexamethasone in patients with t(11;14)-positive relapsed/refractory multiple myeloma.

(2020) Maria-Victoria Mateos et al.   JOURNAL OF CLINICAL ONCOLOGY

Pomalidomide, dexamethasone, and daratumumab in relapsed refractory multiple myeloma after lenalidomide treatment

(2020) David S. Siegel et al.   LEUKEMIA

Histone Deacetylases (HDACs): Evolution, Specificity, Role in Transcriptional Complexes, and Pharmacological Actionability

(2020) Giorgio Milazzo et al.   Genes

Filanesib in combination with pomalidomide and dexamethasone in refractory MM patients: safety and efficacy, and association with alpha 1‐acid glycoprotein (AAG) levels. Phase Ib/II Pomdefil clinical trial conducted by the Spanish MM group

(2020) Enrique M. Ocio et al.   BRITISH JOURNAL OF HAEMATOLOGY

A Phase I Trial Evaluating Vorinostat plus Bortezomib, Lenalidomide and Dexamethasone in Patients with Newly Diagnosed Multiple Myeloma

(2020) Jonathan L. Kaufman et al.   Clinical Lymphoma Myeloma & Leukemia

The roles of histone variants in fine-tuning chromatin organization and function

(2020) Sara Martire et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY

Molecular mechanisms of thalidomide and its derivatives

(2020) Takumi ITO et al.   PROCEEDINGS OF THE JAPAN ACADEMY SERIES B-PHYSICAL AND BIOLOGICAL SCIENCES

Melphalan and exportin 1 inhibitors exert synergistic anti-tumor effects in preclinical models of human multiple myeloma

(2020) Joel G Turner et al.   CANCER RESEARCH

Peptide and Small Molecule Inhibitors Targeting Myeloid Cell Leukemia 1 (Mcl-1) as Novel Antitumor Agents

(2020) Xing Lu et al.   CURRENT MOLECULAR MEDICINE

Pomalidomide, bortezomib, and dexamethasone for multiple myeloma previously treated with lenalidomide (OPTIMISMM): outcomes by prior treatment at first relapse

(2020) Meletios Dimopoulos et al.   LEUKEMIA

Epigenetic Aberrations in Multiple Myeloma

(2020) Cinzia Caprio et al.   Cancers

Targeting BCL ‐2 with venetoclax and dexamethasone in patients with relapsed/refractory t(11;14) multiple myeloma

(2020) Jonathan L. Kaufman et al.   AMERICAN JOURNAL OF HEMATOLOGY

Bortezomib, Vorinostat, and Dexamethasone Combination Therapy in Relapsed Myeloma: Results of the Phase 2 MUK four Trial

(2020) Sarah Brown et al.   Clinical Lymphoma Myeloma & Leukemia

Small-Molecule Approaches to Targeted Protein Degradation

(2020) Tyler B. Faust et al.   Annual Review of Cancer Biology-Series

Ixazomib – the first oral proteasome inhibitor

(2019) Jingmei Xie et al.   LEUKEMIA & LYMPHOMA

The multiple mechanisms that regulate p53 activity and cell fate

(2019) Antonina Hafner et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY

Cancer statistics for African Americans, 2019

(2019) Carol E. DeSantis et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Phase 1 study of selinexor plus carfilzomib and dexamethasone for the treatment of relapsed/refractory multiple myeloma

(2019) Andrzej J. Jakubowiak et al.   BRITISH JOURNAL OF HAEMATOLOGY

Incidence of opportunistic infections during ibrutinib treatment for B-cell malignancies

(2019) Kerry A. Rogers et al.   LEUKEMIA

TAS4464, a highly potent and selective inhibitor of NEDD8 activating enzyme, suppresses neddylation and shows antitumor activity in diverse cancer models

(2019) Chihoko Yoshimura et al.   MOLECULAR CANCER THERAPEUTICS

Population pharmacokinetics of pevonedistat alone or in combination with standard of care in patients with solid tumours or haematological malignancies

(2019) Hélène M. Faessel et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Phase 1 study of the MDM2 inhibitor AMG 232 in patients with advanced P53 wild-type solid tumors or multiple myeloma

(2019) W. Larry Gluck et al.   INVESTIGATIONAL NEW DRUGS

T-cell expression of Bruton’s tyrosine kinase promotes autoreactive T-cell activation and exacerbates aplastic anemia

(2019) Simo Xia et al.   Cellular & Molecular Immunology

Selinexor: First Global Approval

(2019) Yahiya Y. Syed   DRUGS

Oral Selinexor–Dexamethasone for Triple-Class Refractory Multiple Myeloma

(2019) Ajai Chari et al.   NEW ENGLAND JOURNAL OF MEDICINE

Anticancer drug discovery by targeting cullin neddylation

(2019) Qing Yu et al.   Acta Pharmaceutica Sinica B

Phase 1 Study of Bisthianostat, an Orally Efficacious Pan-HDAC Inhibitor: Part Results of Safety, Pharmacokinetics and Efficacy in Patients with Relapsed or Refractory Multiple Myeloma

(2019) Hong-Hui Huang et al.   BLOOD

Initial Safety and Efficacy of Dose-Escalating HDACs Inhibitor Chidamide with VRD (Chi-VRD) Treatment for Newly-Diagnosed High-Risk Transplant Eligible Multiple Myeloma Patients

(2019) Jingjing Shang et al.   BLOOD

Phase I Study of a Novel Bcl-2 Inhibitor, at-101 in Combination with Lenalidomide and Dexamethasone in Patients with Relapsed and/or Refractory Multiple Myeloma (RRMM)

(2019) Sikander Ailawadhi et al.   BLOOD

A Phase 1, First-in-Human Study of AMG 176, a Selective MCL-1 Inhibitor, in Patients With Relapsed or Refractory Multiple Myeloma

(2019) Andrew Spencer et al.   Clinical Lymphoma Myeloma & Leukemia

A phase 1 study of filanesib, carfilzomib, and dexamethasone in patients with relapsed and/or refractory multiple myeloma

(2019) Hans C. Lee et al.   Blood Cancer Journal

Gain of Chromosome 1q is associated with early progression in multiple myeloma patients treated with lenalidomide, bortezomib, and dexamethasone

(2019) Timothy M. Schmidt et al.   Blood Cancer Journal

Daratumumab in high‐risk relapsed/refractory multiple myeloma patients: adverse effect of chromosome 1q21 gain/amplification and GEP70 status on outcome

(2019) Meera Mohan et al.   BRITISH JOURNAL OF HAEMATOLOGY

A Phase 2 Study of Ibrutinib in Combination with Bortezomib and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma

(2019) Roman Hajek et al.   EUROPEAN JOURNAL OF HAEMATOLOGY

Filanesib for the treatment of multiple myeloma

(2019) Esperanza Macarena Algarín et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

How the Other Half Lives: What p53 Does When It Is Not Being a Transcription Factor

(2019) Teresa Ho et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Ibrutinib alone or with dexamethasone for relapsed or relapsed and refractory multiple myeloma: phase 2 trial results

(2018) Paul G. Richardson et al.   BRITISH JOURNAL OF HAEMATOLOGY

Targeting the neddylation pathway in cells as a potential therapeutic approach for diseases

(2018) Jie Ying et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Safety and efficacy of vorinostat, bortezomib, doxorubicin and dexamethasone in a phase I/II study for relapsed or refractory multiple myeloma (VERUMM study: vorinostat in elderly, relapsed and unfit multiple myeloma)

(2018) Johannes M. Waldschmidt et al.   HAEMATOLOGICA

Safety and efficacy of vorinostat, bortezomib, doxorubicin and dexamethasone in a phase I/II study for relapsed or refractory multiple myeloma (VERUMM study: vorinostat in elderly, relapsed and unfit multiple myeloma)

(2018) Johannes M. Waldschmidt et al.   HAEMATOLOGICA

Ibrutinib and Aspergillus: a Btk-targeted risk

(2018) Jennifer A. Woyach   BLOOD

A Cereblon Modulator (CC-220) with Improved Degradation of Ikaros and Aiolos

(2017) Mary E. Matyskiela et al.   JOURNAL OF MEDICINAL CHEMISTRY

From basic apoptosis discoveries to advanced selective BCL-2 family inhibitors

(2017) Avi Ashkenazi et al.   NATURE REVIEWS DRUG DISCOVERY

Promoting tumorigenesis in nasopharyngeal carcinoma, NEDD8 serves as a potential theranostic target

(2017) Ping Xie et al.   Cell Death & Disease

Current Review on High-Risk Multiple Myeloma

(2017) Henry S. H. Chan et al.   Current Hematologic Malignancy Reports

Replication Study: BET bromodomain inhibition as a therapeutic strategy to target c-Myc

(2017) Fraser Aird et al.   eLife

Molecular signaling in multiple myeloma: association of RAS/RAF mutations and MEK/ERK pathway activation

(2017) J Xu et al.   Oncogenesis

Enhancement of pomalidomide anti-tumor response with ACY-241, a selective HDAC6 inhibitor

(2017) Brian J. North et al.   PLoS One

Identification of a p53-based portable degron based on the MDM2-p53 binding region

(2016) Adam T. Melvin et al.   ANALYST

Bromodomains: Structure, function and pharmacology of inhibition

(2016) Elena Ferri et al.   BIOCHEMICAL PHARMACOLOGY

Clonal selection and double-hit events involving tumor suppressor genes underlie relapse in myeloma

(2016) N. Weinhold et al.   BLOOD

A novel alkylating agent Melflufen induces irreversible DNA damage and cytotoxicity in multiple myeloma cells

(2016) Arghya Ray et al.   BRITISH JOURNAL OF HAEMATOLOGY

A phase 1 dose-escalation study of filanesib plus bortezomib and dexamethasone in patients with recurrent/refractory multiple myeloma

(2016) Ajai Chari et al.   CANCER

VANTAGE 095: An International, Multicenter, Open-Label Study of Vorinostat (MK-0683) in Combination With Bortezomib in Patients With Relapsed and Refractory Multiple Myeloma

(2016) David S. Siegel et al.   Clinical Lymphoma Myeloma & Leukemia

Vemurafenib in combination with cobimetinib in relapsed and refractory extramedullary multiple myeloma harboring the BRAF V600E mutation

(2016) Ulrich J.M. Mey et al.   HEMATOLOGICAL ONCOLOGY

Treatment of acquired drug resistance in multiple myeloma by combination therapy with XPO1 and topoisomerase II inhibitors

(2016) Joel G. Turner et al.   Journal of Hematology & Oncology

Identification of a Benzoisoxazoloazepine Inhibitor (CPI-0610) of the Bromodomain and Extra-Terminal (BET) Family as a Candidate for Human Clinical Trials

(2016) Brian K. Albrecht et al.   JOURNAL OF MEDICINAL CHEMISTRY

Expanding the Cancer Arsenal with Targeted Therapies: Disarmament of the Antiapoptotic Bcl-2 Proteins by Small Molecules

(2016) Jeremy L. Yap et al.   JOURNAL OF MEDICINAL CHEMISTRY

Ricolinostat plus lenalidomide, and dexamethasone in relapsed or refractory multiple myeloma: a multicentre phase 1b trial

(2016) Andrew J Yee et al.   LANCET ONCOLOGY

Elevated Translation Initiation Factor eIF4E Is an Attractive Therapeutic Target in Multiple Myeloma

(2016) S. Li et al.   MOLECULAR CANCER THERAPEUTICS

The Transactivation Domains of the p53 Protein

(2016) Nitin Raj et al.   Cold Spring Harbor Perspectives in Medicine

Bromodomain inhibitor OTX015 in patients with lymphoma or multiple myeloma: a dose-escalation, open-label, pharmacokinetic, phase 1 study

(2016) Sandy Amorim et al.   Lancet Haematology

The proteasome deubiquitinase inhibitor VLX1570 shows selectivity for ubiquitin-specific protease-14 and induces apoptosis of multiple myeloma cells

(2016) Xin Wang et al.   Scientific Reports

Panobinostat plus bortezomib and dexamethasone in previously treated multiple myeloma: outcomes by prior treatment

(2015) P. G. Richardson et al.   BLOOD

CC-122, a pleiotropic pathway modifier, mimics an interferon response and has antitumor activity in DLBCL

(2015) P. R. Hagner et al.   BLOOD

Phase I study of carfilzomib, lenalidomide, vorinostat, and dexamethasone in patients with relapsed and/or refractory multiple myeloma

(2015) David H. Vesole et al.   BRITISH JOURNAL OF HAEMATOLOGY

Synergistic anti-myeloma activity of the proteasome inhibitor marizomib and the IMiD®immunomodulatory drug pomalidomide

(2015) Deepika S. Das et al.   BRITISH JOURNAL OF HAEMATOLOGY

Lenalidomide and vorinostat maintenance after autologous transplant in multiple myeloma

(2015) Douglas W. Sborov et al.   BRITISH JOURNAL OF HAEMATOLOGY

Phase I Study of the Novel Investigational NEDD8-Activating Enzyme Inhibitor Pevonedistat (MLN4924) in Patients with Relapsed/Refractory Multiple Myeloma or Lymphoma

(2015) J. J. Shah et al.   CLINICAL CANCER RESEARCH

The investigational proteasome inhibitor ixazomib for the treatment of multiple myeloma

(2015) Paul G Richardson et al.   Future Oncology

Activity of everolimus (RAD001) in relapsed and/or refractory multiple myeloma: a phase I study

(2015) A. Gunther et al.   HAEMATOLOGICA

Targeting the TGFβ pathway for cancer therapy

(2015) Cindy Neuzillet et al.   PHARMACOLOGY & THERAPEUTICS

Targeting BET bromodomains for cancer treatment

(2015) Marie Jung et al.   Epigenomics

Activity of everolimus (RAD001) in relapsed and/or refractory multiple myeloma: a phase I study

(2015) A. Gunther et al.   HAEMATOLOGICA

Abstract 5531: OTX015, a novel BET inhibitor, is a promising anticancer agent for multiple myeloma

(2015) Maria Todaro et al.   CANCER RESEARCH

Phase I study of the MEK inhibitor trametinib in combination with the AKT inhibitor afuresertib in patients with solid tumors and multiple myeloma

(2014) Anthony W. Tolcher et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Vemurafenib Response in 2 Patients With Posttransplant Refractory BRAF V600E–Mutated Multiple Myeloma

(2014) J.P. Sharman et al.   Clinical Lymphoma Myeloma & Leukemia

Dysregulated Class I histone deacetylases are indicators of poor prognosis in multiple myeloma

(2014) Sridurga Mithraprabhu et al.   Epigenetics

Overactivated Neddylation Pathway as a Therapeutic Target in Lung Cancer

(2014) Lihui Li et al.   JNCI-Journal of the National Cancer Institute

Lenalidomide induces degradation of IKZF1 and IKZF3

(2014) Jan Krönke et al.   OncoImmunology

Cyclin-Dependent Kinase Inhibitor Dinaciclib Interacts with the Acetyl-Lysine Recognition Site of Bromodomains

(2013) Mathew P. Martin et al.   ACS Chemical Biology

Discovery of RG7388, a Potent and Selective p53–MDM2 Inhibitor in Clinical Development

(2013) Qingjie Ding et al.   JOURNAL OF MEDICINAL CHEMISTRY

Vorinostat or placebo in combination with bortezomib in patients with multiple myeloma (VANTAGE 088): a multicentre, randomised, double-blind study

(2013) Meletios Dimopoulos et al.   LANCET ONCOLOGY

Genome-wide studies in multiple myeloma identify XPO1/CRM1 as a critical target validated using the selective nuclear export inhibitor KPT-276

(2013) J Schmidt et al.   LEUKEMIA

CRM1 inhibition induces tumor cell cytotoxicity and impairs osteoclastogenesis in multiple myeloma: molecular mechanisms and therapeutic implications

(2013) Y-T Tai et al.   LEUKEMIA

Bruton's tyrosine kinase: potential target in human multiple myeloma

(2013) Ying Liu et al.   LEUKEMIA & LYMPHOMA

A Small Molecule Inhibitor of Ubiquitin-Specific Protease-7 Induces Apoptosis in Multiple Myeloma Cells and Overcomes Bortezomib Resistance

(2012) Dharminder Chauhan et al.   CANCER CELL

The bromodomain interaction module

(2012) Panagis Filippakopoulos et al.   FEBS LETTERS

Tyrosine Kinase Btk Is Required for NK Cell Activation

(2012) Yan Bao et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Molecular and Cellular Effects of NEDD8-Activating Enzyme Inhibition in Myeloma

(2012) D. W. McMillin et al.   MOLECULAR CANCER THERAPEUTICS

BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-Myc

(2011) Jake E. Delmore et al.   CELL

Clinical and biological implications of MYC activation: a common difference between MGUS and newly diagnosed multiple myeloma

(2011) W-J Chng et al.   LEUKEMIA

Lysine Acetylation Targets Protein Complexes and Co-Regulates Major Cellular Functions

(2009) C. Choudhary et al.   SCIENCE

HDAC expression and clinical prognosis in human malignancies

(2008) Wilko Weichert   CANCER LETTERS